Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
28 Mar 2024
28 Mar 2024
Historique:
received:
14
09
2023
accepted:
23
02
2024
revised:
15
02
2024
medline:
29
3
2024
pubmed:
29
3
2024
entrez:
29
3
2024
Statut:
aheadofprint
Résumé
Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.
Identifiants
pubmed: 38548962
doi: 10.1038/s41375-024-02204-y
pii: 10.1038/s41375-024-02204-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.
doi: 10.1056/NEJMoa1609324
pubmed: 28273028
pmcid: 5901965
Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Mayer J, Brümmendorf TH, et al. Treatment free remission after nilotinib plus peg-interferon alpha induction and peg-interferon alpha maintenance therapy for newly diagnosed chronic myeloid leukemia patients; the tiger trial. Blood. 2023;142:446.
doi: 10.1182/blood-2023-182792
Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57.
doi: 10.1016/S1470-2045(18)30192-X
pubmed: 29735299
Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.
doi: 10.1038/leu.2017.63
pubmed: 28218239
pmcid: 5508077
Mahon F-X, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.
doi: 10.1016/S1470-2045(10)70233-3
pubmed: 20965785
Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–54.
doi: 10.1182/blood-2016-09-742205
pubmed: 27932374
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.
doi: 10.1200/JCO.2016.68.2914
pubmed: 28095277
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.
doi: 10.1182/blood-2013-02-483750
pubmed: 23704092
Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103:1835–42.
doi: 10.3324/haematol.2018.194894
pubmed: 29976734
pmcid: 6278957
Hehlmann R, Saußele S, Voskanyan A, Silver RT. Management of CML-blast crisis. Best Pract Res Clin Haematol. 2016;29:295–307.
doi: 10.1016/j.beha.2016.10.005
pubmed: 27839570
Copland M. Treatment of blast phase chronic myeloid leukaemia: a rare and challenging entity. Br J Haematol. 2022;199:665–78.
doi: 10.1111/bjh.18370
pubmed: 35866251
pmcid: 9796596
Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023;37:5–17.
doi: 10.1038/s41375-022-01736-5
pubmed: 36309558
Hehlmann R. How I treat CML blast crisis. Blood. 2012;120:737–47.
doi: 10.1182/blood-2012-03-380147
pubmed: 22653972
Sokal JE. Evaluation of survival data for chronic myelocytic leukemia. Am J Hematol. 1976;1:493–500.
doi: 10.1002/ajh.2830010414
pubmed: 795294
Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014;32:3077.
doi: 10.1200/JCO.2014.56.0904
pubmed: 25002733
DeFilipp Z, Khoury HJ. Management of advanced-phase chronic myeloid leukemia. Curr Hematol Malig Rep. 2015;10:173–81.
doi: 10.1007/s11899-015-0249-2
pubmed: 25929768
Kantarjian HM, Cortes J, O’Brien S, Giles FJ, Albitar M, Rios MB, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–53.
doi: 10.1182/blood.V99.10.3547
pubmed: 11986206
Silver RT, Cortes J, Waltzman R, Mone M, Kantarjian H. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009;94:743–4.
doi: 10.3324/haematol.2009.006999
pubmed: 19407320
pmcid: 2675690
Cortes J, Kim D-W, Raffoux E, Martinelli G, Ritchie E, Roy L, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008;22:2176–83.
doi: 10.1038/leu.2008.221
pubmed: 18754032
Giles FJ, Kantarjian HM, le Coutre PD, Baccarani M, Mahon F-X, Blakesley RE, et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2012;26:959–62.
doi: 10.1038/leu.2011.355
pubmed: 22157807
Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.
doi: 10.1056/NEJMoa1306494
pubmed: 24180494
Gambacorti-Passerini C, Kantarjian HM, Kim D-W, Khoury HJ, Turkina AG, Brümmendorf TH, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755–68.
doi: 10.1002/ajh.24034
pubmed: 26040495
pmcid: 5132035
Sembill S, Ampatzidou M, Chaudhury S, Dworzak M, Kalwak K, Karow A, et al. Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations. Leukemia. 2023;37:505–17.
doi: 10.1038/s41375-023-01822-2
pubmed: 36707619
pmcid: 9991904
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.
doi: 10.1182/blood-2006-02-005686
pubmed: 16709930
Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19.
doi: 10.1038/s41375-022-01613-1
pubmed: 35732831
pmcid: 9252913
Lauseker M, Bachl K, Turkina A, Faber E, Prejzner W, Olsson-Strömberg U, et al. Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. Am J Hematol. 2019;94:1236–43.
doi: 10.1002/ajh.25628
pubmed: 31456269
Hehlmann R, Voskanyan A, Lauseker M, Pfirrmann M, Kalmanti L, Rinaldetti S, et al. High-risk additional chromosomal abnormalities at low blast counts herald death by CML. Leukemia. 2020;34:2074–86.
doi: 10.1038/s41375-020-0826-9
pubmed: 32382082
pmcid: 7387244
Clark RE, Apperley JF, Copland M, Cicconi S. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021;5:1102–9.
doi: 10.1182/bloodadvances.2020003570
pubmed: 33616651
pmcid: 7903225
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.
doi: 10.1038/s41375-020-0776-2
pubmed: 32127639
pmcid: 7214240
Pfirrmann M, Clark RE, Prejzner W, Lauseker M, Baccarani M, Saussele S, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia. 2020;34:2138–49.
doi: 10.1038/s41375-020-0931-9
pubmed: 32601376
pmcid: 7387299
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: cohort study of 477 patients. Cancer. 2017. https://doi.org/10.1002/cncr.30864 .
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, et al. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol. 2021;14:94.
doi: 10.1186/s13045-021-01106-1
pubmed: 34130720
pmcid: 8204504
Chen Z, Medeiros LJ, Kantajian HM, Zheng L, Gong Z, Patel KP, et al. Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia. Blood Cancer J. 2017;7:e521.
doi: 10.1038/bcj.2017.4
pubmed: 28157214
pmcid: 5386338
Strati P, Kantarjian H, Thomas D, O’Brien S, Konoplev S, Jorgensen JL, et al. HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer. 2014;120:373–80.
doi: 10.1002/cncr.28433
pubmed: 24151050
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transpl. 2019;25:2008–16.
doi: 10.1016/j.bbmt.2019.06.028
Kim T, Tyndel MS, Kim HJ, Ahn J-S, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129:38–47.
doi: 10.1182/blood-2016-04-708560
pubmed: 27733357
Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132:948–61.
doi: 10.1182/blood-2018-02-832253
pubmed: 29967129
Schönfeld L, Rinke J, Hinze A, Nagel SN, Schäfer V, Schenk T, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia. 2022;36:2242–9.
doi: 10.1038/s41375-022-01648-4
pubmed: 35902731
pmcid: 9417980
Ochi Y, Yoshida K, Huang Y-J, Kuo M-C, Nannya Y, Sasaki K, et al. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. Nat Commun. 2021;12:2833.
doi: 10.1038/s41467-021-23097-w
pubmed: 33990592
pmcid: 8121838
CML-1: Understanding the clonal hierarchy in Chronic Myeloid Leukemia to help improve patient outcomes. https://www.harmony-alliance.eu/projects/research-project/cml-understanding-the-clonal-hierarchy-in-chronic-myeloid-leukemia-to-help-improve-patient-outcomes-1655723411 (accessed 11 Feb2024).
Copland M, Slade D, McIlroy G, Horne G, Byrne JL, Rothwell K, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol. 2022;9:e121–e132.
doi: 10.1016/S2352-3026(21)00370-7
pubmed: 34906334
Deau B, Nicolini FE, Guilhot J, Huguet F, Guerci A, Legros L, et al. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leuk Res. 2011;35:777–82.
doi: 10.1016/j.leukres.2010.11.004
pubmed: 21145590